Literature DB >> 11372760

Elevated serum-soluble Fas ligand in histiocytic necrotizing lymphadenitis.

K Kato1, K Ohshima, K Anzai, J Suzumiya, M Kikuchi.   

Abstract

Recent studies have indicated that Fas and perforin-based mechanisms seem to induce apoptosis in histiocytic necrotizing lymphadenitis (HNL). In this study, we evaluated the serum levels of soluble Fas ligand (sFasL) in 30 HNL patients using paired sera. Elevations in sFasL levels were detected in 9 patients in the active stage. In the convalescent stage, the levels of sFasL decreased to an undetectable degree after 2 weeks. These findings indicate the possibility that sFasL plays an important role in the constitutional symptoms and pathogenesis of HNL and, furthermore, that it can act as a surrogate marker of the disease activity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11372760     DOI: 10.1007/bf02981907

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  6 in total

1.  Viral regulation of CD95 expression and apoptosis in T lymphocytes.

Authors:  S Sieg; Y Huang; D Kaplan
Journal:  J Immunol       Date:  1997-08-01       Impact factor: 5.422

2.  Elevation of the serum Fas ligand in patients with hemophagocytic syndrome and Diamond-Blackfan anemia.

Authors:  D Hasegawa; S Kojima; E Tatsumi; A Hayakawa; Y Kosaka; H Nakamura; M Sako; Y Osugi; S Nagata; K Sano
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

3.  Lethal effect of the anti-Fas antibody in mice.

Authors:  J Ogasawara; R Watanabe-Fukunaga; M Adachi; A Matsuzawa; T Kasugai; Y Kitamura; N Itoh; T Suda; S Nagata
Journal:  Nature       Date:  1993-08-26       Impact factor: 49.962

4.  Elevated serum soluble Fas ligand in natural killer cell proliferative disorders.

Authors:  K Kato; K Ohshima; S Ishihara; K Anzai; J Suzumiya; M Kikuchi
Journal:  Br J Haematol       Date:  1998-12       Impact factor: 6.998

5.  Fas ligand in human serum.

Authors:  M Tanaka; T Suda; K Haze; N Nakamura; K Sato; F Kimura; K Motoyoshi; M Mizuki; S Tagawa; S Ohga; K Hatake; A H Drummond; S Nagata
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

6.  Expression of the functional soluble form of human fas ligand in activated lymphocytes.

Authors:  M Tanaka; T Suda; T Takahashi; S Nagata
Journal:  EMBO J       Date:  1995-03-15       Impact factor: 11.598

  6 in total
  4 in total

1.  Overlap between systemic lupus erythematosus and Kikuchi Fujimoto disease: a clinical pathology conference held by the Department of Rheumatology at Hospital for Special Surgery.

Authors:  Jessica K Gordon; Cynthia Magro; Theresa Lu; Robert Schneider; April Chiu; Richard R Furman; Garron Solomon; Anne Bass; Doruk Erkan
Journal:  HSS J       Date:  2009-07-16

Review 2.  Co-occurrence of Kikuchi-Fujimoto's disease and Still's disease: case report and review of previously reported cases.

Authors:  Karen A Toribio; Hideko Kamino; Stephanie Hu; Miriam Pomeranz; Michael H Pillinger
Journal:  Clin Rheumatol       Date:  2014-08-08       Impact factor: 2.980

3.  A Challenging Case of Kikuchi-Fujimoto Disease Associated with Systemic Lupus Erythematosus and Review of the Literature.

Authors:  Mihaela Găman; Ana-Maria Vlădăreanu; Camelia Dobrea; Minodora Onisâi; Cristina Marinescu; Irina Voican; Daniela Vasile; Horia Bumbea; Diana Cîşleanu
Journal:  Case Rep Hematol       Date:  2018-01-23

4.  Histiocytic necrotising lymphadenitis (Kikuchi-Fujimoto disease) in Saudi Arabia: clinicopathology and immunohistochemistry.

Authors:  Jaudah Al-Maghrabi; Hassan Kanaan
Journal:  Ann Saudi Med       Date:  2005 Jul-Aug       Impact factor: 1.526

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.